ArticleInfectious microbes & diseases2020
Azithromycin Exerts Bactericidal Activity and Enhances Innate Immune Mediated Killing of MDR
Article in Infectious microbes & diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Overcoming Ceftaroline Resistance in MRSA Using Ceftaroline-Carbapenem Combination Therapy.Open forum infectious diseases · 2026Article
- Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2025Review
- Enhanced Killing of Methicillin-Resistant Staphylococcus aureus With Ceftaroline or Vancomycin in Combination With Carbapenems.The Journal of infectious diseases · 2025Article
- Mutations in Genes with a Role in Cell Envelope Biosynthesis Render Gram-Negative Bacteria Highly Susceptible to the Anti-Infective Small Molecule D66.Microorganisms · 2025Article
- Rapid valve sterilization with meropenem plus ceftolozane/tazobactam combination therapy forJAC-antimicrobial resistance · 2025Article
- Ethylenediaminetetraacetic Acid Enhances Vancomycin and Reactive Oxygen Species-Mediated Killing of Vancomycin-IntermediateOpen forum infectious diseases · 2025Article
- Advancing antibiotic discovery with bacterial cytological profiling: a high-throughput solution to antimicrobial resistance.Frontiers in microbiology · 2025Review
- Re-evaluation of FDA-approved antibiotics with increased diagnostic accuracy for assessment of antimicrobial resistance.Cell reports. Medicine · 2023Article
- Designing mRNA- and Peptide-Based Vaccine Construct against Emerging Multidrug-ResistantMedicina (Kaunas, Lithuania) · 2022Article
- Azithromycin: An Underappreciated Quinolone-Sparing Oral Treatment forAntibiotics (Basel, Switzerland) · 2022Article
- Assessment of the in vitro activity of azithromycin niosomes alone and in combination with levofloxacin on extensively drug-resistant Klebsiella pneumoniae clinical isolates.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021Article
- Evaluation of the Whole Proteome ofFrontiers in medicine · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Azithromycin (AZM), the most commonly prescribed antibiotic in the United States, is thought to have no activity against multidrug-resistant Gram-negative pathogens such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.